NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
Clinical Trials
13 trialsNCT05104866 2026-02-04
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Phase 3 Active not recruiting
NCT02954055 2024-02-26
METEORA-II
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT00128310 2023-05-31
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT01835236 2021-03-30
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Swiss Cancer Institute
Phase 2 Completed
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT01441596 2015-09-07
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Boehringer Ingelheim
Phase 2 Completed
NCT01242449 2015-05-21
OVINTRA
Vejle Hospital
Phase 2 Completed
NCT00795678 2013-08-02
Chemotherapeutic Agents in Brain/Breast
Case Comprehensive Cancer Center
Completed
NCT00476827 2013-07-17
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Duke University
Phase 2 Terminated
NCT00629148 2011-07-07
Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)
Fudan University
Phase 2 Completed
NCT01126138 2011-05-04
Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)
ChineseAMS
Phase 3 Unknown